Filtered By:
Drug: Temodar

This page shows you your search results in order of date.

Order by Relevance | Date

Total 98 results found since Jan 2013.

Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells
This study aimed to understand the potential role and molecular mechanism of the combination therapy of B7H6-siRNA and temozolomide in glioblastoma cancer. U87 cells were treated with B7H6-siRNA and temozolomide, separately and in combination. Cell viability, stemness, cell migration, and apoptosis were measured. The results of this work presented the synergistic effect of B7H6-siRNA and temozolomide in inhibiting the cancerous features of the U87 cell line. Down-regulating B7H6-siRNA expression inhibited the cell viability of U87 glioblastoma cancer cells and increased their sensitivity to temozolomide. In addition, a not...
Source: Experimental Cell Research - May 29, 2023 Category: Cytology Authors: Nadia Allahyarzadeh Khiabani Mohammad Amin Doustvandi Fateme Mohammadnejad Elnaz Salmani Hassan Kohal Neda Boushehri Mahdi Jafarlou Behzad Baradaran Source Type: research

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
Drug Deliv. 2023 Dec;30(1):1-13. doi: 10.1080/10717544.2022.2152911.ABSTRACTTemozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties. O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme, which can repair the DNA damage caused by TMZ. A large number of clinical data show that reducing the expression of MGMT can enhance the chemotherapeutic efficacy of TMZ. Therefore, in order to improve the resistance of glioma to TMZ, an angiopep-2 (A2) modified nanoprodrug of polytemozolomide (P(TMZ)n) tha...
Source: Drug Delivery - December 29, 2022 Category: Drugs & Pharmacology Authors: Haoyue Xu Yongkang Zhang Linfeng Li Yanhong Ren Feng Qian Lansheng Wang Hongwei Ma Ankang Quan Hongmei Liu Rutong Yu Source Type: research

Atypical induction of HIF-1 α expression by pericellular Notch1 signaling suffices for the malignancy of glioblastoma multiforme cells
Cell Mol Life Sci. 2022 Oct 2;79(10):537. doi: 10.1007/s00018-022-04529-2.ABSTRACTContact-based pericellular interactions play important roles in cancer progression via juxtacrine signaling pathways. The present study revealed that hypoxia-inducible factor-1α (HIF-1α), induced even in non-hypoxic conditions by cell-to-cell contact, was a critical cue responsible for the malignant characteristics of glioblastoma multiforme (GBM) cells through Notch1 signaling. Densely cultured GBM cells showed enhanced viability and resistance to temozolomide (TMZ) compared to GBM cells at a low density. Ablating Notch1 signaling by a γ-...
Source: Cellular and Molecular Life Sciences : CMLS - October 2, 2022 Category: Cytology Authors: Jungwhoi Lee Eunsoo Kim Kyuha Chong Seung-Wook Ryu Chungyeul Kim Kyungsun Choi Jae-Hoon Kim Chulhee Choi Source Type: research

STAT5b is a marker of poor prognosis, rather than a therapeutic target in glioblastomas
In conclusion, STAT5b is frequently activated in GBM and correlates inversely with patient survival. It does not contribute to the growth and resistance of these tumors, and is thus rather a potential prognostic marker than a therapeutic target in these tumors.PMID:36069226 | DOI:10.3892/ijo.2022.5414
Source: International Journal of Oncology - September 7, 2022 Category: Cancer & Oncology Authors: Nad ège Dubois Sharon Berendsen Katherine Tan Laurent Schoysmans Wim Spliet Tatjana Seute Vincent Bours Pierre A Robe Source Type: research

MicroRNA-640 Inhibition Enhances the Chemosensitivity of Human Glioblastoma Cells to Temozolomide by Targeting Bcl2 Modifying Factor
Biochem Genet. 2022 Aug 19. doi: 10.1007/s10528-022-10264-x. Online ahead of print.ABSTRACTGlioblastoma (GBM) is the most malignant and challenging type of astrocytoma and also notoriously acknowledged as the most common primary brain tumor globally. Currently, chemotherapy is the most master therapy for tumor and is essential in clinical treatment for GBM. Nevertheless, the characterization of chemotherapy resistance seriously hinders clinical chemotherapy treatment. Accordingly, there are imperious demands for the exploitation of novel chemosensitizer to promote the efficacy of chemotherapy. Our current study was conduct...
Source: Biochemical Genetics - August 19, 2022 Category: Genetics & Stem Cells Authors: Shu Jiang Chao Luo Yongli Chen Jing Chen Shuang Tao Quan Zou Chunzhi He Shanwu Dong Source Type: research

Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma
In this study, we utilize the engineering technology to generate T7 peptide-decorated exosome (T7-exo). T7 is a peptide specifically binding to the transferrin receptor. T7-exo shows excellent packaging and protection of cholesterol-modified Cy3-siYY1 while quickly releasing payloads in a cytoplasmic reductive environment. The engineered exosomes T7-siYY1-exo could deliver more effciently to GBM cells both in vitro and in vivo. Notably, in vitro experiments demonstrate that T7-siYY1-exo can enhance chemoradiotherapy sensitivity and reverse therapeutic resistance. Moreover, T7-siYY1-exo and TMZ/IR exert synergistic anti-GBM...
Source: Frontiers in Pharmacology - August 19, 2022 Category: Drugs & Pharmacology Source Type: research

Intelligent Nanoparticles With pH-Sensitive Co-Delivery of Temozolomide and siEGFR to Ameliorate Glioma Therapy
In this study, pH-sensitive and GBM-targeting nanovesicle (Tf-PEG-PAE(SS)) was fabricated. The chemotherapy drug (TMZ) and EGFR inhibitor (EGFR-siRNA) were co-encapsulated in the nanocarrier, and their anticancer outcomes were investigated in detail. In vitro experiments have shown that the nanocarrier transports TMZ and EGFR-siRNA efficiently into U87 cells, causing a vigorous apoptotic response by silencing the proliferative EGFR gene and increasing the drug concentration of TMZ simultaneously. An experimental study in mice bearing orthotropic glioma revealed that the accumulated nanocarriers in the tumor site could inhi...
Source: Frontiers in Genetics - July 12, 2022 Category: Genetics & Stem Cells Source Type: research

Cancers, Vol. 14, Pages 1984: SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma
Okay Saydam Extracellular vesicles (EVs) may be used as a non-invasive screening platform to discover markers associated with early diagnosis, prognosis, and treatment response. Such an approach is invaluable for diseases such as glioblastoma, for which only a few non-invasive diagnostic or prognostic markers are available. We used mass spectrometry to analyze proteomics profiles of EVs derived from four glioblastoma cell lines and human primary astrocytes (HPAs) and found that SRPX is the only protein enriched in the majority of glioblastoma EVs that was absent in the HPA-derived EVs. Then, we evaluated the relationsh...
Source: Cancers - April 14, 2022 Category: Cancer & Oncology Authors: Elisabet Ampudia-Mesias Samia El-Hadad Charles Scott Cameron Adelheid W öhrer Thomas Str öbel Nurten Saydam Okay Saydam Tags: Article Source Type: research

TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway
In conclusion, these results demonstrate the functional role of the TRPC5-NFATc3-P-gp signalling pathway in TMZ resistance in glioblastoma cells.PMID:34500231 | DOI:10.1016/j.tranon.2021.101214
Source: Translational Oncology - September 9, 2021 Category: Cancer & Oncology Authors: Yan Zou Zi'xiang Liu Yi'nan Zhou Jing Wang Qin'yi Xu Xu'dong Zhao Zeng'li Miao Source Type: research